Gene Association: CIITA

UniProt Search: CIITA (PROTEIN_CODING)
Function Description: class II major histocompatibility complex transactivator

found 10 associated metabolites with current gene based on the text mining result from the pubmed database.

24,25-Dihydrolanosterol

(3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol

C30H52O (428.4018)


24,25-dihydrolanosterol is a 3beta-sterol formed from lanosterol by reduction across the C-24-C-25 double bond. It has a role as a human metabolite and a mouse metabolite. It is a 3beta-sterol and a tetracyclic triterpenoid. It is functionally related to a lanosterol. 24,25-Dihydrolanosterol is a natural product found in Euphorbia sapinii, Heterobasidion annosum, and other organisms with data available. 24,25-dihydrolanosterol is a metabolite found in or produced by Saccharomyces cerevisiae. 24,25-Dihydrolanosterol is involved in the biosynthesis of steriods. 24,25-Dihydrolanosterol is reversibly converted to lanosterol by delta24-sterol reductase [EC:1.3.1.72]. A 3beta-sterol formed from lanosterol by reduction across the C-24-C-25 double bond. 24,25-Dihydrolanosterol (Lanostenol) is a component of the seeds of red pepper (Capsicum annuum)[1].

   

(5Z)-(15S)-11alpha-Hydroxy-9,15-dioxoprostanoate

(5Z)-7-[(1S,2S,3S)-3-hydroxy-5-oxo-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid

C20H32O5 (352.225)


(5Z)-(15S)-11alpha-Hydroxy-9,15-dioxoprostanoate is a precursor in producing (5Z)-(15S)-11-a-hydroxy-9,15-dioxoprosta-13-enoate in the presence of NADP+, in this reaction (5Z)-(15S)-11alpha-Hydroxy-9,15-dioxoprostanoate is oxidized. [HMDB] (5Z)-(15S)-11alpha-Hydroxy-9,15-dioxoprostanoate is a precursor in producing (5Z)-(15S)-11-a-hydroxy-9,15-dioxoprosta-13-enoate in the presence of NADP+, in this reaction (5Z)-(15S)-11alpha-Hydroxy-9,15-dioxoprostanoate is oxidized.

   

Xanthochymol

3-(3,4-dihydroxybenzoyl)-4-hydroxy-8,8-dimethyl-5-[5-methyl-2-(prop-1-en-2-yl)hex-5-en-1-yl]-1,7-bis(3-methylbut-2-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione

C38H50O6 (602.3607)


Xanthochymol is found in fruits. Xanthochymol is a constituent of the famine food Garcinia xanthochymus

   

Tamibarotene

4-((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)benzoic acid

C22H25NO3 (351.1834)


Tamibarotene is only found in individuals that have used or taken this drug. It is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.Tamibarotene is a specific agonist for retinoic acid receptor alpha/beta with possible binding to retinoid X receptors (RXR). C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent Same as: D01418

   

13,14-Dihydro-15-keto-PGE2

(5Z)-7-[(1R,2R,3R)-3-hydroxy-5-oxo-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid

C20H32O5 (352.225)


13,14-dihydro-15-keto-PGE2 is one of the prostaglandin E2 metabolites. (PMID 7190512) Human fetal lung in vitro has the competence to self-differentiate, as early as 12 weeks gestation and presence of high levels in fetal lung of the inactive metabolite 13,14-dihydro-15-keto-PGE2 relative to PGE2 suggests that active prostaglandin catabolism may be one of the mechanisms to retard this stage of maturation in vivo by limiting PGE2 availability. (PMID 8835315)Dinoprostone is a naturally occurring prostaglandin E2 (PGE2) and the most common and most biologically active of the mammalian prostaglandins. It has important effects in labour and also stimulates osteoblasts to release factors which stimulate bone resorption by osteoclasts (a type of bone cell that removes bone tissue by removing the bones mineralized matrix). PGE2 has been shown to increase vasodilation and cAMP production, to enhance the effects of bradykinin and histamine, to induce uterine contractions and to activate platelet aggregation. PGE2 is also responsible for maintaining the open passageway of the fetal ductus arteriosus; decreasing T-cell proliferation and lymphocyte migration and activating the secretion of IL-1alpha and IL-2. PGE2 exhibits both pro- and anti-inflammatory effects, particularly on dendritic cells (DC). Depending on the nature of maturation signals, PGE2 has different and sometimes opposite effects on DC biology. PGE2 exerts an inhibitory action, reducing the maturation of DC and their ability to present antigen. PGE2 has also been shown to stimulate DC and promote IL-12 production when given in combination with TNF-alpha. PGE2 is an environmentally bioactive substance. Its action is prolonged and sustained by other factors especially IL-10. It modulates the activities of professional DC by acting on their differentiation, maturation and their ability to secrete cytokines. PGE2 is a potent inducer of IL-10 in bone marrow-derived DC (BM-DC), and PGE2-induced IL-10 is a key regulator of the BM-DC pro-inflammatory phenotype. (PMID: 16978535)Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 13,14-dihydro-15-keto-PGE2 is one of the prostaglandin E2 metabolites. (PMID 7190512) Human fetal lung in vitro has the competence to self-differentiate, as early as 12 weeks gestation and presence of high levels in fetal lung of the inactive metabolite 13,14-dihydro-15-keto-PGE2 relative to PGE2 suggests that active prostaglandin catabolism may be one of the mechanisms to retard this stage of maturation in vivo by limiting PGE2 availability. (PMID 8835315)

   

FA 20:4;O3

4-((1S,2S,5R)-5-hydroxy-2-((S,1E,5Z)-3-hydroxyundeca-1,5-dien-1-yl)-3-oxocyclopentyl)butanoic acid

C20H32O5 (352.225)


D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents

   

Tamibarotene

Tamibarotene

C22H25NO3 (351.1834)


C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent

   

CHEBI:28113

(3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol

C30H52O (428.4018)


   

13,14-dihydro-15-keto-PGE2

13,14-dihydro-15-keto Prostaglandin E2

C20H32O5 (352.225)


   

Am 80

Tamibarotene

C22H25NO3 (351.1834)


C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent Same as: D01418